Purpose of review: Gene expression profiling has highlighted the biologic heterogeneity of breast cancer and has begun to influence the ability of the medical community to individualize patient therapy. The review is intended to highlight the most important advances in the field over recent years with an emphasis on those most relevant to the practicing oncologist.
Recent findings: Two prognostic profiling assays, the Mammaprint and Oncotype Dx, are in phase III clinical trials designed to evaluate their contribution to therapeutic decision making. Predictive profiles for both chemotherapy and targeted therapy are also in development. In addition, application of genetic profiling techniques to a variety of tumor types is starting to identify those processes, like proliferation, that are integral to carcinogenesis as a whole.
Summary: The biologic heterogeneity of breast cancer has become clearer through genome-wide profiling technologies. Validation of the clinical utility of prognostic profiles may enable oncologists to better identify those patients whose prognosis justifies more intensive therapy, while predictive profiles may soon be able to determine which type of chemotherapy a patient should receive. In addition, profiling is starting to identify new therapeutic targets which will point the field of breast cancer oncology in new directions.